Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452363 | 1.00 | DRD2 (0.30) | DRD2HTR1DDRD3 | |
| SCHEMBL21199457 | 1.00 | DRD2 (0.30) | DRD2HTR1DDRD3 | |
| SCHEMBL30683357 | 0.86 | CXCR2 (0.32) | DRD2HTR1DDRD3 | |
| SCHEMBL14857160 | 0.86 | CXCR2 (0.32) | DRD2HTR1DDRD3 | |
| SCHEMBL14857161 | 0.84 | NR1H2 (0.34) | — | |
| SCHEMBL15388623 | 0.84 | NR1H2 (0.34) | — | |
| SCHEMBL4063484 | 0.78 | KIF11 (0.37) | DRD2DRD3 | |
| SCHEMBL4038267 | 0.78 | KIF11 (0.37) | DRD2DRD3 | |
| SCHEMBL12295990 | 0.75 | NR1H2 (0.34) | — | |
| SCHEMBL13403393 | 0.73 | MMP2 (0.34) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | ANOVIA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023076567-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| WO-2023042914-A1 | PYRROLIDINE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | WO | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DRD2 4707/4885HTR1D 4782/4885DRD3 4835/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | DRD2 4697/4885HTR1D 4783/4885DRD3 4827/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | DRD2 4707/4885HTR1D 4782/4885DRD3 4835/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DRD2 4697/4885HTR1D 4783/4885DRD3 4827/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | DRD2 3796/4885HTR1D 2902/4885DRD3 4122/4885 |
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | DRD2 3454/4885HTR1D 2729/4885DRD3 3000/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DRD2 4707/4885HTR1D 4782/4885DRD3 4835/4885 |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | LOX, LOXL1, LOXL2 | DRD2 4273/4885HTR1D 3343/4885DRD3 4460/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | DRD2 3796/4885HTR1D 2902/4885DRD3 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.